Thomas D. Nguyen

Thomas D. Nguyen

Auto-generated profile, based on publicly available information

Thomas D. Nguyen

Division of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
AEArne Echterhof
Arne Echterhof
TDTejas Dharmaraj
Tejas Dharmaraj
PBPatrick M. Blankenberg
Patrick M. Blankenberg
BTBobby Targ
Bobby Targ
TNThomas D. Nguyen
Thomas D. Nguyen
FBFrancis G. Blankenberg
Francis G. Blankenberg
Bacteriophage (phage) therapy holds great promise for treating antimicrobial-resistant infections. However, the pharmacokinetics (PK) of phage have been difficult to characterize due to a lack of standardized protocols for phage purification, labeling, and in vivo quantification. Here, we present robust methods for ultrapure phage preparation, as well as non-destructive, highly stable attachment of radio-iodide to phage using a well-described Sulfo-SHPP linker. We purified and radiolabeled the phage strains, PAML-31-1, OMKO1, and Luz24, lytic to drug-resistant Pseudomonas aeruginosa, for biodistribution assay in normal young adult CD-1 mice injected via intravenous injection. Groups of five mice were euthanized, and tissues/organs were removed for weighing and scintillation well counting of 125 I activity. A physiologically based PK model was then constructed, focusing on compartments describing blood, lung, muscle, bone, liver, stomach, spleen, small intestines, large intestines, and kidney. Tissue partition coefficients (K P ) were estimated for high-perfusion organs (lung and kidney) as 0.000138, GI organs (liver, spleen, and stomach) as 0.627, and all other organs as 0.220. Monte Carlo simulations predicted rapid elimination of phage in humans, with blood concentrations being <10 2 PFU/mL by 12 h, whereas simulated multi-dose regimens and continuous infusion regimens were predicted to have sustained concentrations. Our physiologically based PK model of phage represents the first rigorous preclinical assessment of phage PK utilizing contemporary pharmacometric approaches amenable to both preclinical and clinical study design.

23 July 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
TNThomas D. Nguyen
Thomas D. Nguyen
NSNicholas Smith
Nicholas Smith
KAKris Attwood
Kris Attwood
AGAijaz Gundroo
Aijaz Gundroo
SCShirley Chang
Shirley Chang
KTKathleen M. Tornatore
Kathleen M. Tornatore
Study Objective: The objective was to compare tacrolimus AUC0‐12 determined by Non‐Compartmental Analysis (NCA) using intensive sampling to Maximum a Posteriori‐Bayesian (MAP‐Bayesian) estimates from robust (n = 9 samples/subject) and sparse (n = 2 samples/subject) sampling in 67 stable KTRs and a validation group of similar patients.Design: This open‐label, prospective, single center 12‐h PK study included nine serial samples collected in KTRs to determine steady‐state NCA tacrolimus AUC0‐12.Setting: This study was conducted at a single site within a large, urban hospital in the western New York area.Patients: This study described tacrolimus pharmacokinetics in stable kidney transplant recipients on maintenance tacrolimus therapy.Intervention: Robust and sparse AUC0‐12 estimates by a MAP‐Bayesian approach were obtained using the Advanced Dosing Solutions (AdDS) and ADAPT5 freeware. Limited sampling strategies were evaluated using the original population PK model (n = 67), which was also assessed using a validation group (n = 15). AUC0‐12 agreement was tested by paired t‐tests with intraclass correlation coefficient (ICC) and Bland Altman analysis.Measurements and Main Results: A total of 35 Black and 32 White stable KTRs (estimated glomerular filtration rate [eGFR] = 55.2 ± 15.7 mL/min/1.73m2) received the tacrolimus dose of 3.4 ± 1.7 mg/study with troughs of 6.8 ± 1.8 ng/mL. The NCA‐AUC0‐12 was 123.8 ± 33.6 μg·h/L compared to MAP‐Bayesian estimates for Robust‐AUC0‐12 of 124.7 ± 33.3 μg·h/L and optimal 2‐specimen Sparse‐AUC0‐12 of 119.7 ± 32.7 μg·h/L for the training group. Comparison of Robust‐AUC0‐12 to NCA‐AUC0‐12 had an ICC of 0.96 (p = 0.99) while comparison of Robust‐AUC0‐12 to Sparse‐AUC0‐12 using Pre‐dose trough [C(t0h)] and 1 h [C(t1h)] resulted in an ICC of 0.93 (p = 0.014). In the validation group, 5 Black and 10 White KTRs (eGFR = 56.4 ± 16.8 mL/min/1.73m2) received a mean tacrolimus dose of 1.9 ± 1.2 mg/study with a trough of 6.0 ± 1.7 ng/mL. The validation group's NCA‐AUC0‐12 (88.4 ± 33.1 μg·h/L) was comparable to Robust‐AUC0‐12 (85.1 ± 33.8 μg·h/L, ICC = 0.93; p = 0.12) and Sparse‐AUC0‐12 determined from C(t0h) and C(t4h) (86.7 ± 33.9 μg·h/L, ICC = 0.91; p = 0.61).Conclusion: MAP‐Bayesian estimation for patient‐specific AUC0‐12 using sparse, two‐specimen sampling is comparable to NCA and may enhance tacrolimus TDM in stable KTRs.

21 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NSNicholas Smith
Nicholas Smith
TNThomas D. Nguyen
Thomas D. Nguyen
TLthomas patrick lodise
thomas patrick lodise
LCLiang Chen
Liang Chen
JKJan Naseer Kaur
Jan Naseer Kaur
BTBrian T. Tsuji
Brian T. Tsuji

7 January 2026 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
TNThomas D Nguyen
Thomas D Nguyen
JSJacob T Sanborn
Jacob T Sanborn
BHBrian M Ho
Brian M Ho
TLTiffany Luong
Tiffany Luong
TWTroy D Wood
Troy D Wood
NSNicholas Smith
Nicholas Smith
Background: There is a resurgence of interest in bacteriophage (phage) therapy as antimicrobials, resulting from growing antimicrobial resistance to small-molecule antibiotics. Phages are bacterial viruses long studied, but there is a need for high resolution and systematic assessment of clinical dosing strategies for phages to better inform therapy. Methods: We hypothesized that empirical in vitro assessment of clinically relevant phages facilitates pharmacodynamic-driven individualization. Three clinically relevant phage strains (LUZ19, PYO2 and E215) were evaluated as mono- or dual-phage therapy against a clinical Pseudomonas aeruginosa in 24 h static time kills and in 7-day hollow fibre infection model. Results: PYO2 single-bolus administration achieved a bacterial log reduction of 6.82 log10 cfu/mL, with eradication at 4 h. Dual-phage therapy (LUZ19 + PYO2) achieved a bacterial log reduction of 6.81 log10 cfu/mL, with delayed eradication at 12 h. Conclusions: This highlights the potential of reverse translational pharmacokinetic/pharmacodynamic-driven approaches to guide rational phage selection strategies against individual clinical isolates while identifying potential antagonistic phage–phage interactions.

7 October 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
CHClaire Han
Claire Han
KPKarishma Patel
Karishma Patel
HGHaoran Gao
Haoran Gao
JSJacob T. Sanborn
Jacob T. Sanborn
TNThomas D. Nguyen
Thomas D. Nguyen
NSNicholas Smith
Nicholas Smith
Nosocomial Pseudomonas aeruginosa infections are among the most challenging infections to treat, and resistance to last-line agents, including polymyxins and aztreonam-based therapies, risks a future with limited or no clinical treatment options. Bacteriophages (phages) have emerged as a promising therapeutic option, both in cocktails and when given in combination with antibiotics. In this study, we show that the synergy between a lipopolysaccharide (LPS)-specific phage and antibiotics is driven by clinically relevant increases in beta-lactam permeability due to the selection of phage-resistant subpopulations. First, in the Hollow Fiber Infection Model (HFIM), we show that the combination of phage LUZ19 (pili-targeted), phage E215 (LPS-specific), and aztreonam (ATM) eradicated the laboratory host PAO1, whereas monotherapy with neither phage nor ATM could eradicate PAO1. Static time-kill studies (STKS) evaluated the LPS-specific phage PYO2 in combination with either aztreonam/avibactam (ATM/AVI) or polymyxin B (PMB) against an extensively drug-resistant clinical isolate of P. aeruginosa (AR-0231). PYO2 combined with ATM/AVI was determined to be synergistic, with a mean excess-over-bliss (EOB) of 0.350 ( P < 0.05), while PYO2 with PMB was also synergistic, with a mean EOB of 0.361 ( P < 0.05). Linear regression of STKS using sequential administration showed that, compared to antibiotic-first treatment, phage-first treatment reduced bacterial concentrations at 24 h by −6.19 log 10 colony-forming unit (CFU)/mL ( P < 0.05), with statistically significant interactions estimated for each antibiotic. These results indicated that bacterial pre-selection by PYO2 improved antibiotic activity. Mass spectrometry studies showed that the PYO2-resistant AR-0231 strain exhibited a >25% increase in the outer membrane permeability surface area coefficient for all major anti- Pseudomonal beta-lactams, including aztreonam. Altogether, our study provides mechanistic insights into phage-induced collateral sensitivity of beta-lactams. These results show how specific beta-lactams can be prioritized and optimized in phage-antibiotic combinations to maximize the antibacterial activity.

29 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
TNThomas D. Nguyen
Thomas D. Nguyen
CGConnor E. Gould
Connor E. Gould
JSJacob T. Sanborn
Jacob T. Sanborn
JTJoshua Tutin
Joshua Tutin
YPYan Pan
Yan Pan
NSNicholas Smith
Nicholas Smith
Bacteriophages are a promising therapeutic class against drug-resistant bacterial infections but require analytical methods meeting modern drug development standards. Plaque-based enumeration, the gold standard, is laborious, host-dependent, and highly variable. Targeted mass spectrometry of virion structural proteins offers an orthogonal, host-independent, scalable alternative. Here, we describe a targeted proteomic LC-MS/MS assay for the Pseudomonas aeruginosa podovirus LUZ19. Peptide mapping identified multiple structural proteins, providing 55% sequence coverage of a LUZ19 major capsid protein, from which the signature peptide EVAELDGQELAR was selected for quantitation. Using multiple reaction monitoring, calibrators and quality controls were evaluated across three independent runs, with calibrator bias of −7.0 to 4.6%, intra-day precision of 0.5 to 9.3%, and inter-day precision of 6.6 to 12.0%. Peptide concentrations were related to plaque-assay titers by weighted Deming regression, yielding an empirical copy number of 1,314 (95% CI: 1,098 to 1,529) peptide copies per PFU and a phage-equivalent concentration. This proof-of-concept study establishes the analytical foundation for a fully validated assay.